Milgamma N (Benfotiamine, Cyanocobalamin, Pyridoxine Hydrochloride)

Benfotiamine is a lipid‑soluble form of thiamine that is converted to thiamine pyrophosphate, a co‑enzyme in carbohydrate metabolism. Cyanocobalamin is transformed into active cobalamin cofactors essential for DNA synthesis and nerve function. Pyridoxine is metabolised to pyridoxal‑5‑phosphate, a co‑enzyme for amino‑acid metabolism and neurotransmitter synthesis. Together they support metabolic pathways and neuronal health.

The appropriate dose of Milgamma N is determined by the prescribing healthcare professional based on the individual’s clinical condition, age, and other factors. Patients should follow the dosage instructions provided by their prescriber and not adjust the amount without medical advice.

Safety data for Milgamma N in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss use with their physician, who can weigh potential benefits against any theoretical risks.

To place an order, submit an enquiry on the Milgamma N product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Milgamma N combines three specific B‑vitamins—benfotiamine, cyanocobalamin and pyridoxine—in a formulation designed for enhanced bioavailability, especially for benfotiamine. Compared with generic B‑complex tablets, it may offer better absorption of thiamine and targeted support for neuropathic conditions, though clinical outcomes depend on individual patient factors.

Milgamma N should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and keep out of reach of children.

Milgamma N is taken orally, usually with water. It can be taken with or without food, unless the prescribing clinician advises otherwise. Swallow the tablet whole; do not crush or chew unless instructed.

Serious adverse reactions are rare but may include hypersensitivity such as rash, swelling, anaphylaxis, severe skin eruptions, significant changes in blood counts, or liver enzyme abnormalities. Patients should seek immediate medical attention if they experience any signs of a severe allergic reaction or unexplained systemic symptoms.

Milgamma N should be avoided by individuals with known hypersensitivity to any of its components (benfotiamine, cyanocobalamin, pyridoxine) or by patients for whom a healthcare professional has contraindicated its use, such as those with certain rare metabolic disorders affecting B‑vitamin metabolism.